32.74

2.15% 0.69

After Hours: 31.49 -1.25 -3.82%

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $32.74, with a volume of 469.78K. It is up +2.15% in the last 24 hours and up +15.93% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$32.05

Open:

$31.76

24h Volume:

469.78K

Relative Volume:

0.96

Market Cap:

$2.27B

Revenue:

Net Income/Loss:

$-179.27M

P/E Ratio:

-12.79

EPS:

-2.56

Net Cash Flow:

$-155.88M

1W Performance:

+3.18%

1M Performance:

+15.93%

6M Performance:

+66.53%

1Y Performance:

+124.55%

1-Day Range:

$31.12

$32.75

1-Week Range:

$30.12

$32.95

52-Week Range:

$13.39

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

11:42 AM

Akero Therapeutics COO sells $1.6 million in stock By Investing.com - Investing.com South Africa

11:42 AM

11:33 AM

Akero Therapeutics COO sells $1.6 million in stock - Investing.com India

11:33 AM

10:08 AM

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in Stock - MarketBeat

10:08 AM

09:19 AM

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com South Africa

09:19 AM

09:18 AM

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com India

09:18 AM

Nov 04, 2024

abrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Nov 04, 2024

Nov 02, 2024

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat

Nov 02, 2024

Nov 01, 2024

Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com South Africa

Nov 01, 2024

Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com

Nov 01, 2024

Oct 29, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat

Oct 29, 2024

Oct 27, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat

Oct 27, 2024

Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire

Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan

Oct 21, 2024

Oct 20, 2024

Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St

Oct 20, 2024

Oct 19, 2024

(AKRO) Proactive Strategies - Stock Traders Daily

Oct 19, 2024

Oct 18, 2024

Andrew Cheng Sells 24,992 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Oct 18, 2024

Akero Therapeutics CEO Andrew Cheng sells $2.88 million in stock By Investing.com - Investing.com Canada

Oct 18, 2024

Akero Therapeutics chief development officer sells $636,490 in stock By Investing.com - Investing.com South Africa

Oct 18, 2024

Akero Therapeutics chief development officer sells $636,490 in stock - Investing.com India

Oct 18, 2024

Oct 17, 2024

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares - GuruFocus.com

Oct 17, 2024

Akero therapeutics COO Jonathan Young sells $1.2 million in stock By Investing.com - Investing.com Australia

Oct 17, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Rheos Capital Works Inc. - MarketBeat

Oct 17, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decrease in Short Interest - MarketBeat

Oct 17, 2024

Oct 16, 2024

Akero therapeutics COO Jonathan Young sells $1.2 million in stock - Investing.com

Oct 16, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 Shares - MarketBeat

Oct 16, 2024

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin - Insider Monkey

Oct 16, 2024

Oct 15, 2024